Capsugel Xcelodose® System Automating the Preparation of Test Articles and Clinical Trial Supplies

The pharmaceutical development director of today is under enormous pressure to progress new molecules through early phase development as rapidity as possible and at reasonable cost. In research, great progress has been made to reap the benefits of combinatorial chemistry and to provide potential new chemical entities (NCEs) for the company pipeline. For all leading pharmaceutical companies investment in research is high, but costs escalate further when the molecule enters the full development phase. Recent estimates indicate that a delay of jsut a single day can cost a pharmaceutical company between US$1 million and US$30,000 per day and is rising by 10 to 12 per cent per annum.
Download Article